What the Study Found (In Plain English)
Published in Climacteric : the journal of the International Menopause Society (2018), this meta-analysis evaluating human clinical outcomes investigated: Postmenopausal hormone therapy (HT) is a modifiable risk factor for venous thromboembolism (VTE). Key clinical takeaway: Among women using opposed oral estrogen, there was higher VTE risk in women using medroxyprogesterone acetate (RR 2.77, 95% CI 2.33-3.30) than in those using other progestins.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Climacteric : the journal of the International Menopause Society, 2018-08-15; Meta-Analysis; Rigor 86/100): Among women using opposed oral estrogen, there was higher VTE risk in women using medroxyprogesterone acetate (RR 2.77, 95% CI 2.33-3.30) than in those using other progestins.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.